AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02149407
Drug: Glycerin
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerin group GG will receive the 0.5 suppository (700 mg) twice daily for 48 hours. We will use the rounded part and discard the other part then will hold baby's buttocks for 2 minutes to ensure its delivery.
Trial: NCT03603197
Drug: BP-C1
RxNorm normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
Trial: NCT03486899
Drug: BMS-986036
RxNorm normalized name: BMS-986036
DrugBank: Pegbelfermin (DB15365)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days.
Trial: NCT04431687
Drug: CKD 501
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT01729897
Drug: Etomidate
RxNorm normalized name: Etomidate
DrugBank: Etomidate (DB00292)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01729897
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00372333
Drug: IDEA-033
RxNorm normalized name: ALUMINUM ZIRCONIUM OCTACHLOROHYDREX GLY 16.4 g in 100 g TOPICAL GEL [Dry Idea Antiperspirant]
DrugBank: Aluminum zirconium octachlorohydrex gly (DB11200)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00770705
Drug: Phenoxybenzamine
RxNorm normalized name: Phenoxybenzamine
DrugBank: Phenoxybenzamine (DB00925)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The drug will be administered in the operating room. After induction of anesthesia and the pIacement of appropriate cardiovascular monitoring lines, an initial loading dose of 0.25 mg/kg will be administered intravenously immediately prior to cardiopulmonary bypass.For up to 72 hours postoperatively, 0.25 mg/kg/day will be administered Based on published pharmacokinetic data these doses should block 90 -95% of alpha-peripheral receptors with a half life of 24 - 36 hours for regeneration.
Trial: NCT00085553
Drug: Erlotinib Hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00085553
Drug: Tipifarnib
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00035269
Drug: Antibiotic
RxNorm normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01398852
Drug: Riboflavin
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riboflavin is a solution that will be delivered to the treatment area
Trial: NCT01686945
Drug: semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Start doses of 5 mg and 10 mg with end dose of 20 mg. For oral administration.
Trial: NCT01686945
Drug: semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Start doses of 5 mg and 10 mg with end doses of either 20 mg or 40 mg. For oral administration.
Trial: NCT01686945
Drug: semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Start doses of 5 mg and 10 mg with end doses of either 20 mg, 40 mg or 60 mg. For oral administration.
Trial: NCT00545753
Drug: Spinosad
RxNorm normalized name: Spinosad
DrugBank: Spinosad (DB08823)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 minute topical application product, following by a complete rinse off.
Trial: NCT00545753
Drug: Spinosad
RxNorm normalized name: Spinosad
DrugBank: Spinosad (DB08823)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 minute topical application followed by a complete rinse off, followed by a nit combing regimen
Trial: NCT00545753
Drug: Permethrin 1%
RxNorm normalized name: PERMETHRIN 1% LIQUID,TOP
DrugBank: Permethrin (DB04930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
Trial: NCT03473600
Drug: Triamcinolone acetonide injection
RxNorm normalized name: triamcinolone acetonide Injection
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional Triamcinolone Acetonide injection
Trial: NCT00814177
Drug: warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No change: Continue without any change in spite of prothrombin time outside the therapeutic range.
Trial: NCT00814177
Drug: warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Change: Increase one dose in case prothrombin time is below the therapeutic range; delete or reduce one dose in case prothrombin time is above the therapeutic range.
Trial: NCT02944201
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol will give twice daily until prostatectomy
Trial: NCT00568178
Drug: Losartan Potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan Use During the Double-Blind Treatment Phase:~Losartan potassium was administered orally as tablets; 25 or 50 milligrams (mg); or as a liquid suspension 2.5 mg/mL prepared for participants who weighed less than 25 kilograms (kg) or for those participants unable to swallow tablets. During the double-blind period, participants were initially randomized to either a once-daily weight-dependent dose of approximately 0.7 mg/kg (25 mg tablet; up to 50 mg per day) and at 2-weeks the dose was increased to a once-daily maximum weight-dependent dose of 1.4 mg/kg. The maximum dose of losartan, as specified in the protocol, was 50 mg/day (if the patient weighed \<50 kg)~or 100 mg/day (if the patient weighed ≥50 kg).~Losartan Use During the Treatment Extension Phase:~Dose modifications of the drug were left up to the discretion of the Investigators based on each participant's level of tolerance.
Trial: NCT00568178
Drug: Comparator: amlodipine besylate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine besylate (1 mg/mL) liquid suspension, oral administration, titrated to 0.2 mg/kg/day (5 mg maximum dose) per day for 12 Weeks
Trial: NCT00568178
Drug: Enalapril Maleate
RxNorm normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril 2.5-, 5-, 10-, and 20-mg tablets or enalapril suspension (1 mg/mL), oral administration, once daily for 36 months.
Trial: NCT03025113
Drug: Cyclobenzaprine
RxNorm normalized name: Cyclobenzaprine
DrugBank: Cyclobenzaprine (DB00924)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will take 2 tablets (cyclobenzaprine), oral, per day, each 12h.
Trial: NCT01073163
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bendamustine at 90 mg/m\^2 IV on Days 1 and 2 of a 28-day cycle.
Trial: NCT01073163
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab at 375 mg/m\^2 IV on Day 1 of a 28-day cycle.
Trial: NCT01332630
Drug: TPI 287
RxNorm normalized name: TPI-287
DrugBank: TPI-287 (DB17168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose Phase I: 160 mg/m2 by vein over 60 minutes on Days 1, 8, and 15 of every 28 day cycle.~Starting Dose Phase II: Maximum tolerated dose from Phase I.
Trial: NCT01332630
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 mg by mouth at 12 hours and 6 hours prior to treatment. As alternative and based on the treating physician discretion, dexamethasone 10 mg by vein may be given 30-60 minutes prior to treatment with TPI 287.
Trial: NCT01332630
Drug: Benadryl
RxNorm normalized name: Benadryl
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12.5-25 mg intravenous (IV) push 30-60 minutes prior
Trial: NCT01332630
Drug: Ranitidine
RxNorm normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As H2 blocker 1mg/kg IV 30-60 minutes prior
Trial: NCT00559312
Drug: fluticasone/salmeterol combination
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Diskus inhaler, fluticasone 250μg/salmeterol 50μg, twice daily, 6-week duration
Trial: NCT04193293
Drug: Duvelisib
RxNorm normalized name: Duvelisib
DrugBank: Duvelisib (DB11952)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Phosphoinositide 3-kinase (PI3K) Inhibitor
Trial: NCT00489944
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00489944
Drug: sunitinib malate
RxNorm normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00489944
Drug: tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02212925
Drug: BI 14332 CL
RxNorm normalized name: hydroxypropyl bis-hydroxyethyldimonium chloride
DrugBank: Propyl acetate (DB01670)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02586311
Drug: Amlodipine 5mg Placebo
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once a day, 8 weeks
Trial: NCT02586311
Drug: Amlodipine 5mg
RxNorm normalized name: LEVAMLODIPINE 5MG TAB
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once a day, 8 weeks
Trial: NCT02377492
Drug: Vasopressins
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Either paracervical and intramyometrial or intramyometrial alone at time of abdominal myomectomy.
Trial: NCT01084057
Drug: vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01084057
Drug: ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02608385
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab (200 mg) given every 3 weeks.
Trial: NCT01409915
Drug: Sagramostim
RxNorm normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 subjects 250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks. Data and Safety Monitoring Board will then review data and recommend whether to continue at the same current recommended dose for additional subjects or to reduce the dose by half if excessive leukocytosis occurs
Trial: NCT02010905
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00535431
Drug: AER 001
DrugBank: AER001 (DB05078)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg (in nebuliser), twice daily for 28 days
Trial: NCT03989336
Drug: Manganese Chloride
RxNorm normalized name: Manganese Chloride
DrugBank: Manganese citrate (DB14495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered by inhalation at 0.4mg/kg twice per week in the first 3-week cycle, and then inhaled 0.4mg/kg twice in the first week of each 3-week cycle thereafter
Trial: NCT03989336
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously, 180-220mg/m2 on day 2 in a 3-week cycle (day 1 without Manganese priming)
Trial: NCT04110873
Drug: Antroquinonol Capsule 50mg
RxNorm normalized name: Antroquinonol
DrugBank: Antroquinonol (DB12326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive Antroquinonol 50mg per day (QD) on Day 1 for 12 weeks
Trial: NCT04110873
Drug: Antroquinonol Capsule 100mg
RxNorm normalized name: Antroquinonol
DrugBank: Antroquinonol (DB12326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive Antroquinonol 100mg per day (QD) on Day 1 for 12 weeks
Trial: NCT03989336
Drug: Platinum chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously, Cisplatin (60-80mg/m2) or Carboplatin (area under the curve \[AUC\] 4-6 mg/mL per min) on day 2 in a 3-week cycle (day 1 without Manganese priming)
Trial: NCT03989336
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously, 200mg on day 3 in a 3-week cycle (day 2 without Manganese priming)
Trial: NCT01008410
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide will be administered as per the dose and schedule specified in the respective arm.
Trial: NCT01826981
Drug: RBV
RxNorm normalized name: RBV
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Trial: NCT01826981
Drug: Peg-IFN
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pegylated interferon (Peg-IFN) 180 µg administered subcutaneously once weekly
Trial: NCT01826981
Drug: GS-9669
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-9669 500 mg (2 × 250 mg tablet) administered orally once daily
Trial: NCT01302067
Drug: Fesoterodine 8mg
RxNorm normalized name: fesoterodine fumarate 8 MG
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, 1 tablet per day, 12 weeks duration, 8mg/day
Trial: NCT01302067
Drug: Fesoterodine 4mg
RxNorm normalized name: fesoterodine fumarate 4 MG
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, 1 tablet per day, 12 weeks duration, 4mg/day
Trial: NCT01151852
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will be randomly assigned to receive imatinib at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression, unacceptable toxicity, or withdrawal of consent.
Trial: NCT01826981
Drug: VEL
RxNorm normalized name: Velban
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Velpatasvir (VEL) tablet(s) administered orally once daily
Trial: NCT01575418
Drug: Rectal formulation (RF) of tenofovir 1% gel
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The RF is translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg.
Trial: NCT03819790
Drug: Basal insulin glargine and lixisenatide
RxNorm normalized name: insulin glargine and lixisenatide
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Soliqua (insulin glargine and lixisenatide): a titratable combination of long-acting basal insulin glargine and lixisenatide (Glucagon-like peptide-1 receptor agonist)
Trial: NCT03819790
Drug: Basal insulin Basaglar/Lantus + gliclazide MR
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: basal long-acting insulin Basaglar/Lantus with gliclazide MR 60 mg OD
Trial: NCT01575418
Drug: Vaginal formulation (VF) of tenofovir 1% gel
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The original VF is a transparent, viscous gel formulation containing 1% (weight/ weight or w/w) of tenofovir (PMPA, 9-\[(R)-2-(phosphonomethoxy)propyl\]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. This formulation has been used in all clinical trials (vaginal, penile, and rectal) of tenofovir 1% gel to date.
Trial: NCT01575418
Drug: Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified slightly from the original VF formulation, the RGVF has a lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobical effectiveness. The RGVF formulation with 2.75% HEC was used in MTN-007 (CONRAD IND 73,382; currently enrolling), which is the only clinical study of this formulation. The RGVF formulation has since been modified to increase the viscosity.
Trial: NCT03912220
Drug: Nicotinamide riboside
RxNorm normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental arm will investigate the effects of nicotinamide riboside on nerve degeneration and regeneration.
Trial: NCT00151437
Drug: Pegvisomant treatment
RxNorm normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00961779
Drug: NNZ-2566
RxNorm normalized name: NNZ-2591
DrugBank: NNZ-2591 (DB15601)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with bicarbonate buffer and normal saline.
Trial: NCT00669747
Drug: Carboplatin i.d. Days 1 & 15
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin, 10 mg/ml, 10 ml (100 mg) infused into DCIS-involved duct on Days 1 \& 15
Trial: NCT00669747
Drug: Carboplatin i.d. Day 1; Normal Saline i.d. Day 15
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin 10 mg/ml, 10 ml (100 mg) i.d. DCIS duct on Day 1 Normal Saline, 10 ml i.d. DCIS duct on Day 15
Trial: NCT03512353
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone will be taken orally or by IV infusion at a dose of 20 mg once-daily on days 1, 2, 8, 9, 15, 16, 22, and 23 of cycles 1-6, and at a dose 40 mg once-daily on days 1, 8, 15 of cycles 7-12.
Trial: NCT03512353
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carfilzomib will be administered at 20 mg/m² on days 1 and 2 of the first cycle. After that, carfilzomib will be administered at 56 mg/m² on days 8, 9, 15, and 16 of the first cycle, and then on days 1, 2, 8, 9, 15, and 16 on each 28-day cycle for the cycles 2 through 6. Starting with cycle 7 through cycle 12, carfilzomib will be administered at 70 mg/m² on days 1, 8, and 15 of each 28-day cycle. All
Trial: NCT00270101
Drug: epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03819790
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients can be administered with most tolerant dose of metformin
Trial: NCT02793219
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01298180
Drug: Growth hormone (Genotonorm® or Omnitrope®)
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug : the treatment will be begun in progressive dose by beginning by ¼ of the dose the first week, then ½ of the dose the second week, then 3/4 of the dose the third week and total dose the fourth week.
Trial: NCT01060423
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting dose of 400mg/m2, followed by weekly 250mg/m2
Trial: NCT01060423
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan 180 mg/m² to be administered every two weeks
Trial: NCT00356109
Drug: Injectable insulin
RxNorm normalized name: insulin degludec Injectable Solution
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: patient specific dose, injected, before meals, 6 months
Trial: NCT00356109
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patient specific dose, injectable, before meals, 6 months
Trial: NCT01448837
Drug: Bimatoprost/Timolol, 24-hour intraocular pressure monitoring
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered once in the evening
Trial: NCT01448837
Drug: Latanoprost, 24-hour intraocular pressure monitoring
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: assessment of 24-hour efficacy for the two drugs after 3 months of chronic dosing
Trial: NCT00209027
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 30 mg by mouth once daily
Trial: NCT03630159
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti PD-1
Trial: NCT03380871
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: chemotherapy
Trial: NCT03380871
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: chemotherapy